MYLS22
Modify Date: 2025-08-25 18:02:34
MYLS22 structure
|
Common Name | MYLS22 | ||
|---|---|---|---|---|
| CAS Number | 306959-01-3 | Molecular Weight | 443.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H21N5O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MYLS22MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression[1]. |
| Name | MYLS22 |
|---|---|
| Synonym | More Synonyms |
| Description | MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression[1]. |
|---|---|
| Related Catalog | |
| Target |
OPA1[1] |
| In Vivo | MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice[1]. Animal Model: 6-week-old C57BL6/J mice with B16F10 melanomas[1] Dosage: 10 mg/kg/die Administration: Peritumoral injection; every 2 days for 14 days Result: Caused the tumor growth curtailed. |
| References |
| Molecular Formula | C24H21N5O2S |
|---|---|
| Molecular Weight | 443.52 |
| Hazard Codes | Xi |
|---|
| MFCD01062681 |